“Fail faster” is a saying in drug research. In 2014, the Tufts Center for the Study of Drug Development estimated that the average cost of bringing a new drug through the development pipeline and Food and Drug Administration (FDA) approval process to market is $2.6 billion. More than 90 percent of all drugs being developed […]
Celiac Disease Foundation recently administered a survey to gauge community interest in using a simple in-home urine or stool test to monitor gluten intake. Through our iCureCeliac® patient registry, we have found that 53% of people with celiac disease continue to experience symptoms while on a strict gluten-free diet. The most common reason for persistent […]
Celiac Disease Foundation (CDF) and the Gluten Intolerance Group (GIG) are proud to announce a partnership that will improve the health and well-being of the celiac disease and gluten-free communities. n order to create the most comprehensive nonprofit
In addition to improving treatments and finding a cure for celiac disease, iCureCeliac® is helping researchers appreciate the realities of living with celiac disease, helping to influencing what they choose to research and why.
To cure celiac disease we must fundamentally shift how celiac disease research is conceptualized and conducted. Why? Because the current research paradigm for celiac disease, one that has existed for four decades, has not delivered a cure. Not only has it not delivered a cure, celiac disease research has produced only a single approved treatment […]
With more than 1,200 participants registered in its first four months, iCureCeliac™ is shaping the type of research that is most important to you – the patient. We are pleased to present a few initial findings.
Thank you to our more than 1,000 iCureCeliac participants for your amazing commitment to help researchers advance treatments and a cure for celiac disease and gluten sensitivity. We want to hear your concerns about arsenic in your diet, and give you the opportunity to tell us what studies you think should be done.